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We present evidence that pyrrolidine dithiocarbamate (PDTC) inhibits growth of p53-negative pancreatic adenocarcinoma cell lines via cell
cycle arrest in the S-phase, while it has no effect on primary fibroblast proliferation. Growth inhibition of cancer cells is dependent on ROS and
ERK1/2 induction as indicated by a significantly reduced PDTC-associated growth inhibition by the free radical scavenger N-acetyl-L-cysteine
(NAC) or the MEK/ERK1/2 inhibitor (PD98059). Moreover, ERK1/2 induction is dependent on ROS production as demonstrated by a complete
removal of PDTC-mediated ERK1/2 phosphorylation by NAC. p21WAF1/CIP1 activation has a central role in growth inhibition by PDTC, as revealed
by P21WAF1/CIP1 silencing experiments with antisense oligonucleotide, and occurs via increased mRNA stability largely mediated by ROS/ERK
induction. Conversely, PDTC does not affect P21WAF1/CIP1 gene expression in primary fibroblasts, although it is able to activate p53 and the p53-
regulated antioxidant SESN2. These results suggest that the resistance of fibroblasts to the cytotoxic action of PDTC may be related to the up-
regulation of p53-dependent antioxidant genes. Finally, in vivo studies on PaCa44 cells subcutaneously xenografted in nude mice show that
treatment with 100 or 200 mg/kg PDTC reduces of 30% or 60% the tumour volume, respectively, and does not cause any apparent form of toxicity.
© 2006 Elsevier B.V. All rights reserved.Keywords: Pancreatic adenocarcinoma; Pyrrolidine dithiocarbamate; Oxidative stress; ERK1/2; p21WAF1/CIP1; p531. Introduction
Pyrrolidine dithiocarbamate (PDTC) is a synthetic low-mole-
cular-weight thiol compound that has been initially described as
an antioxidant agent [1,2]. However, due to its ionophore pro-
perties [3,4] or the possibility to be enzymatically converted into
the reactive intermediate sulfenic acid [5], PDTCmay also act as a
pro-oxidant agent in vivo.⁎ Corresponding author. Tel.: +39 045 8027169; fax: +39 045 8027170.
E-mail address: marta.palmieri@univr.it (M. Palmieri).
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doi:10.1016/j.bbamcr.2006.05.015It has been reported that the antioxidant activity of PDTC
induces apoptosis in some tumour cell lines, such as colorectal
[2] and prostatic carcinoma cells [6], but may also lead to a
reduction of cell growth inhibition of colorectal cancer cells by
photosensitization [7].
Similarly, the pro-oxidant activity of PDTC has been des-
cribed to induce cell death in human acute myelogenous leu-
kemic cells [8], but also cell proliferation in a murine thymoma
cell model [9]. Therefore, PDTC may be considered as a func-
tionally versatile molecule, which determines either cell death or
cell death prevention depending on the specific cellular model
and micro-environment.
Although themolecular mechanisms underlying PDTC action
are not completely understood, the induction of specific genes
is thought to be responsible for the specific effects on cell
Fig. 1. PDTC inhibits growth of four pancreatic adenocarcinoma cell lines
(PaCa44 ♦, T3M4▪, Panc1▵, CFPAC1○), but not that of primary fibroblasts
(*). PDTC was added at the indicated concentrations for 24 h. Cell proliferation
was determined using the crystal violet colorimetric assay as described in
Materials and methods. Values are the means of triplicate wells from three
independent experiments.
Fig. 2. (A) PDTC determines cell cycle arrest in the S-phase. PaCa44 cells were
treated with 250 μM PDTC for 24 h. Cell cycle distribution was analyzed by a
flow cytometer after DNA staining with propidium iodide. Values are the means
(± SD) of three independent experiments. (B) PDTC does not induce apoptosis.
PaCa44 cells were treated with 250 μM PDTC for 24 h. 2×105 cells were
analyzed by flow cytometry to determine the percentage of cells displaying
annexin V+/propidium iodide− (early apoptosis) or annexin V+/propidium
iodide+ staining (late apoptosis). Values of a representative experiment are
shown.
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PDTC seems to be the activation ofP21WAF1/CIP1 [2], following a
pathway independent of p53, themain transcriptional activator of
P21WAF1/CIP1 [10]. The present study was initiated to investigate
whether PDTC was able to inhibit the growth of p53-negative
human pancreatic adenocarcinoma cell lines. Indeed, pancreatic
cancer is characterized by alterations at high frequency in TP53
[11], whereas it is generally wild type for P21WAF1/CIP1. Despite
advances in the understanding of its molecular biology, gold
standard chemotherapy (5-fluorouracil or gemcitabine) is largely
ineffective [12,13] and prognosis remains dismal with a 5-year
survival of less than 5% [14].
Herein, we show that PDTC specifically inhibits pancreatic
adenocarcinoma cell growth in vitro by P21WAF1/CIP1 mRNA
stabilization mediated by ROS dependent ERK1/2 induction,
while it has no effect on fibroblast proliferation. The latter effect
is most likely due to the ROS scavenging activity of sestrin 2
induced by PDTC-activated p53. We further report that PDTC
treatment significantly inhibits the growth of xenografted
pancreatic adenocarcinoma cells in nude mice.
2. Materials and methods
2.1. Chemicals
Pyrrolidine dithiocarbamate (PDTC) and N-acetyl-L-cysteine (NAC) (Sigma)
were freshly prepared in sterile water. Trichostatin A (TSA) (Sigma) was prepared
in absolute ethanol and stored at −80 °C until use. Diethylmaleate (DEM) was
purchased from Sigma. PD98059, JNK Inhibitor II, SB203580 (Calbiochem)
were prepared in DMSO and stored at −20 °C until use. Actinomycin D (Sigma)
was prepared in sterile water and stored at −20 °C until use.
2.2. Cell culture
Four human pancreatic adenocarcinoma cell lines were studied: PaCa44,
T3M4, Panc1, and CFPAC1 (see [11] for genetic characterization and primary
tissue source). All cell lines were grown in RPMI 1640 supplemented with
20 mM glutamine, 10% FBS and 50 μg/ml gentamicin sulfate (BioWhittaker)
and were incubated at 37 °C with 5% CO2. Primary fibroblasts were grown in
DMEM supplemented with 20 mM glutamine, 10% FBS and 50 μg/ml
gentamicin sulfate and were incubated at 37 °C with 5% CO2.2.3. Cell proliferation assay and P21WAF1/CIP1 silencing
Cells were plated in 96-well plates (4×103 cells/well) and after 24 h treated
with the appropriate compounds (see figure legends) that were left in the
medium for 24 h; then cells were stained with crystal violet (Sigma). The dye
was solubilised in PBS containing 1% SDS and measured photometrically
(A595 nm) to determine cell viability. The phosphorothioate oligonucleotides for
P21WAF1/CIP1 silencing experiments, obtained from Invitrogen, were: antisense
oligonucleotide (p21 AS), 5′-TCCCCAGCCGGTTCTGACAT-3′, sense oligo-
nucleotide (p21 S), 5′-ATGTCAGAACCGGCTGGGGA-3′. Cells were treated
for 24 h with 0.2 μM phosphorothioate oligonucleotides in presence or absence
of 250 μM PDTC and then stained with crystal violet.
2.4. Cell cycle analysis
Cell cycle distribution was analyzed using propidium iodide (PI)-stained
cells. Briefly, 2×105 cells were washed with PBS, incubated with 0.1% sodium
citrate dihydrate, 0.1% Triton X-100, 200 μg/ml RNase A, 50 μg/ml propidium
iodide (Roche Molecular Biochemicals) and analyzed using a flow cytometer
(FACScalibur, Becton Dickinson, Palo Alto, CA). The percentage of cells
in the various stages of the cell cycle was determined using the ModFitLT
software.
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The percentage of apoptotic cells was evaluated by staining 2×105 cells with
annexin V-FITC (Bender Med System, Vienna, Austria) and 5 μg/ml propidium
iodide in binding buffer [10 mM HEPES/NaOH (pH 7.4), 140 mM NaOH, and
2.5 mM CaCl2] for 10 min at room temperature in the dark. The samples were
analyzed by flow cytometry (FACScalibur, Becton-Dickinson) within 1 h to
determine the percentage of cells displaying annexin V+/propidium iodide−
(early apoptosis) or annexin V+/propidium iodide+ staining (late apoptosis).
2.6. Measurement of reactive oxygen species (ROS) production
2′,7′-Dichlorofluorescin (DCF) (Sigma), which is a non-fluorescent probe
becoming highly fluorescent upon reaction with ROS, was used to evaluate
intracellular ROS production. Briefly, 2×105 cells were incubated with 10 μMFig. 3. (A) PDTC determines ROS production in PaCa44 cells, but not in primary fibr
2′,7′-dichlorofluorescin (DCF) fluorescence intensity, corresponding to the level of R
methods. Values are the means (± SD) of three independent experiments. (B) PD98059
250 μM PDTC in the absence or presence of the MEK/ERK inhibitor PD98059 (50
(10 mM) for 24 h. Cell proliferation was determined using the crystal violet colorime
triplicate wells from three independent experiments. Treatment of the cells with the M
(data not shown). (C) DEM inhibits growth of PaCa44 cells (▴), but not that of prima
proliferation was determined using the crystal violet colorimetric assay as described
independent experiments. (D) PDTC induces ROS-dependent ERK1/2 phosphorylat
proteins extracted from PaCa44 cells treated for 1 h with 250 μM PDTC in the abseDCF at 37 °C for 15 min and then fluorescence emission measured by flow
cytometry (FACScalibur, Becton Dickinson).
2.7. Immunoblot analysis
Cells were collected, washed in phosphate-buffered saline, and resuspended
in 20 mMHEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mMNaF,
1 mM Na3VO4, and 1× protease inhibitor cocktail (Roche). After three freeze/
thaw cycles, the lysate was centrifuged at 14,000×g for 10 min at 4 °C and the
supernatant was used for Western blot. Protein concentration was measured with
the Bradford protein assay reagent (Pierce) using bovine serum albumin as a
standard. Twenty-five to fifty micrograms of protein extracts were electro-
phoresed through a 12% SDS-polyacrylamide gel and electro-blotted onto
PVDF membranes (Millipore, Bedford, MA). Membranes were then incubated
overnight at 4 °C with blocking solution [5% low-fat milk in TBST (100 mMoblasts. Cells were treated with 250 μM PDTC and/or 10 mM NAC for 6 h. The
OS production, was measured by flow cytometry as described in Materials and
or NAC reduce cell growth inhibition by PDTC. PaCa44 cells were treated with
μM), JNK Inhibitor II (3 μM), p38 inhibitor SB203580 (30 μM) and/or NAC
tric assay as described in Materials and methods. Values are the means (± SD) of
APK inhibitors and/or NAC in the absence of PDTC did not affect cell growth
ry fibroblasts (▪). DEM was added at the indicated concentrations for 24 h. Cell
in Materials and methods. Values are the means of triplicate wells from three
ion. Western blot analysis of P-ERK1/2 and ERK1/2 was performed using total
nce or presence of PD98059 (50 μM) and/or NAC (10 mM).
Fig. 4. (A) PDTC induces P21WAF1/CIP1 mRNA in PaCa44 cells. RT-PCR
analysis was performed on total RNA obtained from PaCa44 cells or from
primary fibroblasts treated with 250 μM PDTC for 8 h. Primer sequences and
PCR conditions are described in Materials and methods. A representative
experiment is shown. (B) PDTC induces the expression of p21WAF1/CIP1 protein
in PaCa44 cells. Western blot analysis was performed using total protein extract
of PaCa44 cells treated with 250 μM PDTC for 18 h. (C) P21WAF1/CIP1 antisense
oligonucleotide reduces cell growth inhibition by PDTC. PaCa44 cells were
treated for 24 h with 0.2 μM P21WAF1/CIP1 antisense oligonucleotide (p21 AS)
or P21WAF1/CIP1 sense oligonucleotide (p21 S) in the presence of 250 μM PDTC
and then stained with crystal violet to determine cell proliferation. Treatment of
the cells with p21 AS or p21 S alone did not affect cell growth (data not shown).
Values are the means (± SD) of three independent experiments.
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temperature with the appropriate primary antibody (1:1000 in blocking
solution). Horseradish peroxidase conjugated anti-mouse IgG (1:1000 in
blocking solution, Upstate Biotechnology) was used to detect specific proteins.
Immunodetection was carried out using chemiluminescent substrates (Amer-
sham Pharmacia Biotech) and recorded using a HyperfilmECL (Amersham
Pharmacia Biotech). The primary monoclonal antibodies used included anti-
human ERK1/2 (Santa Cruz Biotechnology), anti-human phospho-ERK1/2
(Santa Cruz Biotechnology), anti-human p21WAF1/CIP1 (Upstate Biotechnology),
anti-human phospho-p53 (Ser15) (Cell Signaling Technology), or anti-human
α-tubulin (Oncogene).
2.8. RNA extraction, RT-PCR, and image analysis
Total RNA was extracted from 5×106 cells using TRIzol Reagent
(Invitrogen) and one μg was reverse transcribed using First Strand cDNA
Synthesis (Invitrogen). For each sample, one tenth of the cDNAs was used as
template for PCR amplifications using the following primers and cycling
conditions: p21For 5′-GCGCTAATGGCGGGCTGCAT-3′ and p21Rev 5′-
GCCGGCGTTTGGAGTGGTAG-3′, for 25 cycles of 94 °C for 60 s, 53 °C for
60 s and 72 °C for 60 s; GPXFor 5′-CCAGTTTGGGCATCAGGAG-3′ and
GPXRev 5′-CGATGTCAATGGTCTGGAAG-3′, SESN1For 5′-CGACCAG
GACGAGGAACTT-3′ and SESN1Rev 5′-CCAATGTAGTGACGATAATG
TAGG-3′, SESN2For 5′-TCCGCCACTCAGAGAAGGTC-3′ and SESN2Rev
5′-GTTCAGGAAGGCCACAACAC-3′, for 30 cycles of 94 °C for 30 s, 58 °C
for 30 s and 72 °C for 30 s; β-actinFor 5′-ACCAACTGGGACGACATGGA
GAA-3′ andβ-actinRev 5′-GTGGTGGTGAAGCTGTAGCC-3′, for 25 cycles
of 94 °C for 60 s, 55 °C for 60 s and 72 °C for 60 s. PCR products were separated
by electrophoresis through an ethidium bromide stained 2.0% agarose gel and
visualized with ultraviolet light. Gels were photographed and the bands were
scanned as digital peaks. The areas of the peaks were calculated in arbitrary
units using the public domain NIH Image software (http://rsb.info.nih.gov/nih-
image/). The value of β-actin mRNA was used as a normalizing factor to
evaluate the relative expression levels of P21WAF1/CIP1 mRNA.
2.9. Transient transfection assay
Cells were seeded at a density of 2.5×105 cells in 6-well plates. After 24 h,
cells were transfected using FuGENE6 Transfection Reagent (Roche) with
0.2 μg of a reporter plasmid containing the 2,400 bp upstream to the initiation
transcription site of P21WAF1/CIP1 inserted into the pGL3-Basic vector. At 6 h
after transfection, cells were treated with 250 μM PDTC or 0.2 μM TSA for
different time points. Cell lysates containing an equal amount of proteins were
assayed for luciferase activity using the Luciferase Assay System (Promega).
2.10. In vivo studies
PaCa44 cells (5×106 cells for each mice) were s.c. injected into female nude
mice (4 weeks of age, Harlan, Italy). One week after cell inoculation, 5
randomized animals for each experimental group received vehicle control (PBS)
or PDTC (100 mg/kg or 200 mg/kg) by peritumoral injection twice weekly for
2 weeks. Tumour volume and body weight were biweekly recorded for each
animal. The animal studies were approved by the Verona University Review
Board.
3. Results
3.1. PDTC inhibits growth of pancreatic adenocarcinoma cell
lines by cell cycle S-phase arrest
To test the effect of PDTC on the proliferation of pancreatic
adenocarcinoma cells, we measured the percentage of cell
growth in four p53-negative cell lines after 24 h treatment with
increasing amount of PDTC, compared to untreated cells.
PDTC inhibited the growth of all four cancer cell lines in a dosedependent manner, while it was ineffective on normal human
fibroblasts (Fig. 1).
The analysis of cell cycle distribution and apoptosis in
PaCa44 cells showed that PDTC treatment for 24 h determined a
20% increase of cells in S phase and a corresponding reduction
in G1 phase, compared to untreated cells (Fig. 2A), while it was
unable to induce apoptosis (Fig. 2B). Overlapping results were
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lines examined (data not shown).
3.2. PDTC inhibits cell growth by a ROS/ERK1/2 mediated
mechanism
To explore the molecular mechanisms responsible for PDTC
induced cell cycle arrest, we measured ROS levels after PDTC
treatment. Fig. 3A shows that ROS levels were increased
approximately 2 fold in PDTC-treated PaCa44 cell line, while
they were not affected in normal fibroblasts. Complete depletion
of ROS by the free radical scavenger NAC (Fig. 3A) was able to
significantly increase the percentage of cell growth in PDTC
treated cells (Fig. 3B). That ROS production plays an important
role in PDTC induced cytostatic effect was also confirmed by a
dose dependent proliferation assay showing that NAC was able
to reduce cell growth inhibition at each concentration of PDTC
tested (data not shown). To further verify whether ROS
production was responsible for the differential cytostatic effectFig. 5. (A) PDTC does not determine P21WAF1/CIP1 promoter induction. Transient tran
promoter as described in Materials and methods. After transfection PaCa44 cells w
independent experiments. Sixteen hour PDTC treatment gave similar results. (B) The
PDTC. P21WAF1/CIP1 RT-PCR analysis was performed on total RNA obtained from P
250 μM PDTC and/or actinomycin D. Primer sequences and PCR conditions are d
Densitometric analysis of P21WAF1/CIP1 bands normalized versus β-actin. Values are th
P21WAF1/CIP1 mRNA induction by PDTC. P21WAF1/CIP1 RT-PCR analysis was perform
(50 μM), JNK Inhibitor II (3 μM), SB203580 (30 μM) or NAC (10 mM) and then
described in Materials and methods. A representative experiment is shown.by PDTC on PaCa44 cells and fibroblasts, we performed a
proliferation assay using increasing amount of diethylmaleate
(DEM), a known oxidant agent. As shown in Fig. 3C, DEM
inhibited the growth of the adenocarcinoma cell line in a dose
dependent manner, while it was ineffective on normal human
fibroblasts.
It is known that in some cellular systems, such as smooth
muscle, embryonic kidney, and prostate cancer cells, PDTC is
able to inhibit cell cycle progression by MAP kinases activation
[15–17]. To verify whether pathways including JNK, p38, and
ERK1/2 were involved in growth inhibition of pancreatic cell
lines by PDTC, we tested the effect of inhibitors of these kinases
on the growth of PaCa44 cells. Only PD98059, an inhibitor of
MEK/ERK1/2, was able to increase cell survival by PDTC,
whereas the others were ineffective (Fig. 3B). Moreover, the
addition of NAC to PD98059 did not further increase cell
survival, suggesting that ROS may be responsible for MEK/
ERK1/2 activation. Fig. 3D shows that PDTC was able to
strongly induce ERK1/2 phosphorylation and that this event wassfections were performed with the reporter plasmid containing the P21WAF1/CIP1
ere exposed to PDTC or TSA for 8 h. Values are the means (± SD) of three
presence of actinomycin D does not prevent P21WAF1/CIP1 mRNA induction by
aCa44 cells pre-treated for 1 h with actinomycin D and then treated for 8 h with
escribed in Materials and methods. A representative experiment is shown. (C)
e means (± SD) of three independent experiments. (D) NAC or PD98059 reduce
ed on total RNA extracted from PaCa44 cells pre-treated for 1 h with PD98059
treated for 8 h with 250 μM PDTC. Primer sequences and PCR conditions are
Fig. 6. (A) PDTC promotes p53 phosphorylation in fibroblasts. Fibroblasts were
treated for the indicated times with 250 μM PDTC. Western blot analysis was
performed using total protein extract with anti-p53-phosphoSer15 and anti-α-
tubulin antibodies. (B) PDTC induces SESN2 mRNA in fibroblasts. SESN1,
SESN2, and GPX RT-PCR analysis was performed on total RNA obtained
from PaCa44 cells or fibroblasts treated for 8 h with 250 μM PDTC. Primer
sequences and PCR conditions are described in Materials and methods. A
representative experiment is shown. (C) Densitometric analysis of SESN1,
SESN2, and GPX bands normalized versus β-actin. Values are the means (± SD)
of three independent experiments.
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induction by PDTC depends indeed on ROS production.
3.3. PDTC induces P21WAF1/CIP1 expression in PaCa44 cells
To investigatewhether p21WAF1/CIP1 was involved in cell cycle
arrest by PDTC, we performed an RT-PCR analysis on total
RNAs extracted from PaCa44 cells and fibroblasts before and
after treatment with PDTC. Fig. 4A shows that P21WAF1/CIP1
mRNAwas strongly induced by PDTC in PaCa44 cells, while it
remained at the basal level in fibroblasts. Western blot analysis of
p21WAF1/CIP1 in PaCa44 cells well correlated with the observed
levels of P21WAF1/CIP1 mRNA (Fig. 4B).
To evaluate the functional role of p21WAF1/CIP1 in cell
growth inhibition by PDTC, we performed a cell proliferation
assay using a phosphorothioate antisense oligonucleotide
(p21AS) inhibiting the expression of P21WAF1/CIP1. Treatment
with PDTC and p21AS led to a marked increase of cell survival
when compared to PDTC alone, while treatment with the sense
oligonucleotide (p21 S) did not modify cell growth inhibition
by PDTC (Fig. 4C). The activation of P21WAF1/CIP1 and its
functional role in cell growth inhibition by PDTC was also
confirmed in T3M4 cells (data not shown). Altogether these
data indicate that p21WAF1/CIP1 plays a pivotal role in PDTC-
mediated growth arrest of pancreatic adenocarcinoma cells.
3.4. PDTC induces P21WAF1/CIP1 expression
post-transcriptionally via a ROS/ERK mediated mechanism
To define the molecular mechanisms of P21WAF1/CIP1
mRNA induction by PDTC, we examined the effect of PDTC
on a wild-type P21WAF1/CIP1 promoter-luciferase fusion plasmid
after transient transfection in PaCa44 cells. Following 8 h
exposure to PDTC, luciferase activity from the promoter–
reporter plasmid was not increased compared to untreated cells
(Fig. 5A), while trichostatin A (TSA), a known inducer of
P21WAF1/CIP1 transcription [18], significantly activated the
promoter construct. This result suggested that P21WAF1/CIP1
mRNA enhancement after PDTC treatment was not due to a
transcriptional activation of the gene. Using actinomycin D
treatment of the cells and RT-PCR analysis, we tested whether
PDTC may affect the stability of P21WAF1/CIP1 mRNA. Fig. 5B
and C shows that PDTC was able to induce P21WAF1/CIP1
mRNA also in the presence of actinomycin D and that the ratio
of expression between control and actinomycin D treated cells
was comparable to that obtained in the presence of PDTC.
These data strongly suggest that PDTC increases P21WAF1/CIP1
mRNA levels mainly by enhancing its stability.
To verify whether ROS mediated ERK1/2 induction was
involved in P21WAF1/CIP1 mRNA stabilization by PDTC, we
treated the cells with NAC and PD98059 and evaluated the levels
of the P21WAF1/CIP1 messenger by RT-PCR. Fig. 5D shows that
these compounds significantly reduced P21WAF1/CIP1 induction
by PDTC and that their combination did not further enhance this
effect. These results, in linewith data shown in Fig. 3, demonstrate
that ROS and ERK1/2 are involved in P21WAF1/CIP1 mRNA
induction by PDTC and provide evidence that both signals belongto the same pathway. As expected, treatment of cells with JNKand
p38 inhibitors did not reduce P21WAF1/CIP1 induction by PDTC.
3.5. PDTC induces p53 and the antioxidant SESN2 gene in
fibroblasts
To determine whether p53 was involved in the resistance of
fibroblasts to the cytotoxic action of PDTC, we performed a
Western blot analysis on total cellular proteins from fibroblasts
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phorylated at Ser15. As shown in Fig. 6A, PDTC was able to
induce the phosphorylation of Ser15, which has been previously
reported to mediate the activation of p53 by ROS [19,20]. Then,
we analyzed the effect of PDTC on the expression of theFig. 7. (A) PDTC inhibits PaCa44 cell growth in vivo. PaCa44 cells were
subcutaneously injected into female nude mice. After 1 week, peritumoral
injections with PBS (♦), 100 mg/kg PDTC (□) or 200 mg/kg PDTC (▵) were
carried out twice a week for 2 weeks. Values are the means of tumour volume
measured 3 days after each injection. (B) Tumour volume reduction after four
peritumoral injections with 100 mg/kg or 200 mg/kg PDTC, relative to control.
Values are the means±SD. (C) Mean body mass of mice measured 3 days after
each injection with PBS (♦), 100 (□) or 200 mg/kg PDTC (▵).glutathione peroxidase 1 (GPX1), sestrin 1 (SESN1), and sestrin
2 (SESN2) genes, which are known to be up-regulated by p53
and encode products that act as antioxidants [21]. PDTC
treatment of fibroblasts resulted in a 5.5 fold increase in SESN2
mRNA, whereas the levels of the other two mRNAs remained
unchanged (Fig. 6B and C). In contrast, in PaCa44 cells, which
contain a non-functional TP53, GPX1, SESN1, and SESN2
were not regulated by PDTC. These results suggest that the
resistance of fibroblasts to the cytotoxic action of PDTC may be
related to the up-regulation of p53-dependent antioxidant genes
that scavenge ROS production by PDTC.
3.6. PDTC inhibits pancreatic tumour growth in nude mice
The effect of PDTC on growth inhibition of pancreatic cancer
cells in vivo was examined in nude mice bearing subcutaneous
xenografts of PaCa44 cells. Seven days after s.c. injection of
5×106 PaCa44 cells, five mice for each group were randomized
to receive biweekly peritumoral injection with PBS (vehicle
control) or PDTC for 2 weeks. Fig. 7A and B shows that, at the
end of the study period, PDTC determined at the dose of 100mg/
kg or 200 mg/kg a reduction of the tumour volume of about 30%
and 60%, respectively, compared to control. These treatments
did not produce any toxicity as indicated by lack of change in
mice body mass (Fig. 7C).
4. Discussion
In this study, we have evaluated the in vitro and in vivo
effects of PDTC on human pancreatic adenocarcinoma cell
lines. We have demonstrated that PDTC strongly inhibits in
vitro growth of p53-negative pancreatic adenocarcinoma cell
lines by S-phase cell cycle arrest, while it is ineffective on
normal primary fibroblasts. Furthermore, we have reported that
PDTC increases intracellular ROS levels in PaCa44 cell line and
strongly induces ROS-dependent ERK1/2 phosphorylation.
This induction is largely responsible for the increased stability
of P21WAF1/CIP1 mRNA that plays a central role in PDTC-
mediated growth arrest of pancreatic cancer cells, as demon-
strated by gene silencing with a P21WAF1/CIP1 antisense
oligonucleotide. In contrast, PDTC activates p53 and the p53-
regulated antioxidant SESN2 in primary fibroblasts, which may
be responsible for the resistance of these cells to the cytotoxic
action of the drug. Fig. 8 shows a model of the molecular
mechanisms deduced from our data.
Cellular oxidative stress induced by PDTC may have dif-
ferent origins: (i) increased intracellular concentration of metal
bivalent ions, such as Zn2+, Cu2+, and Fe2+, via its ionophore
activity [3,4]; (ii) inhibition of the (copper/zinc) superoxide
dismutase activity, via its chelating activity [22]; (iii) inhibition
of the glutathione peroxidase activity [23]; (iv) oxidation of
PDTC by microsomal flavin-containing monooxygenases to the
reactive intermediate sulfenic acid, which oxidizes GSH to
GSSG by a nonenzymatic reaction [5]. Our unpublished data
showing that the administration of the metal bivalent ion
chelator N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine
(TPEN) strongly reduces cell growth inhibition by PDTC
Fig. 8. Model of PDTC action on pancreatic adenocarcinoma cells and fibroblasts. The mechanisms identified in this study are shown. See text for further details.
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is mainly due to its ionophore activity.
It has recently been reported that in the absence of severe
stresses relatively low levels of p53 are sufficient for up-regu-
lation of several genes encoding antioxidant proteins, which is
associated with a decrease in intracellular ROS [21]. In the
present study, we have demonstrated that in primary fibroblasts
PDTC is able to induce a low level of p53 phosphorylation at Ser
15. In addition, we show that PDTC up-regulates the p53-
dependent antioxidant SESN2 in fibroblasts but not in pancreatic
adenocarcinoma cells, strongly suggesting that its antioxidant
effect may scavenge ROS production by PDTC and renders
fibroblasts resistant to the cytotoxic action of the drug. This
observation is in line with the emerging belief on the protective
functions of p53 under low stress conditions [21].
Intracellular ROS production may regulate several mechan-
isms associated to the control of cell proliferation [24], supporting
the concept that ROS may be considered as second messengers
[25]. In our cellular system, oxidative stress induced by PDTC
determines a strong phosphorylation of ERK1/2, in line with the
result obtained by Esposito et al. with diethylmaleate on HeLa
cells [26]. ERK1/2 activation is totally inhibited by the
antioxidant molecule NAC, demonstrating that it is strictly
dependent on ROS production. Furthermore, NAC or PD98059
determine a significant reduction of cell growth inhibition by
PDTC, demonstrating that the ROS/ERK pathway plays an
important role in this process. However, as this effect is not
complete, the ROS/ERK1/2 pathway may not be the only
mechanism involved in cell growth inhibition by PDTC. We also
report that the other twoMAPKs, JNK and p38, do not play a rolein cell growth inhibition by PDTC. p21WAF1/CIP1 is one of most
important regulators of the cell cycle [27] and its gene has rarely
been found mutated in human cancers, including pancreatic
cancer [28]. We show here that pancreatic cancer cell growth
inhibition by PDTC is mediated by the increased stability of
P21WAF1/CIP1 mRNA. Our data correlate with the previously
reported results describing P21WAF1/CIP1 induction by ROS/ERK
at post-transcriptional level [26]. Noteworthy, we have observed
that the absence of ROS activation by PDTC in primary
fibroblasts strictly correlates with lack of both P21WAF1/CIP1
induction and cell growth inhibition. Recently, it has been
reported that in breast cancer cells the epidermal growth factor
increases P21WAF1/CIP1 mRNA stability elicited via multiple 3′-
UTR cis-elements [29]. This mechanism may also be involved in
ERK1/2 dependent P21WAF1/CIP1 induction by PDTC in pancrea-
tic cancer cells.
Our results indicate that P21WAF1/CIP1 induction inhibits S-
phase progression, although p21WAF1/CIP1 has been commonly
associated with the arrest in G1 [15] or G2/M phases [30] of the
cell cycle. However, it has also been observed that P21WAF1/CIP1
up-regulation is required for S-phase arrest in human breast
and ovarian cancer cells and that this arrest does not occur in
P21WAF1/CIP1−/− cells [31,32].
Our in vivo experiments showed that peritumoral injections
of PDTC into nude mice bearing a subcutaneous mass of
pancreatic adenocarcinoma cells inhibit tumour growth at doses
of 100 mg/kg or 200 mg/kg. It is noteworthy that these
treatments did not determine any apparent form of toxicity in
vivo, as no mice deaths, body weight variations or other
apparent toxicity-related features were observed. These results
925M. Donadelli et al. / Biochimica et Biophysica Acta 1763 (2006) 917–926correlate with the observation that PDTC determines a specific
cyto-toxicity in vitro against tumour cells (our results and [8]).
In conclusion, our data clearly demonstrate that PDTC
specifically inhibits pancreatic adenocarcinoma cell growth in
vitro by P21WAF1/CIP1 mRNA stabilization mediated by ROS
dependent ERK1/2 induction and that fibroblasts are protected
from PDTC growth inhibition most likely because of the ROS
scavenging activity of sestrin 2 induced by PDTC-activated
p53. Furthermore, in vivo inhibition of xenografted pancreatic
cancer cell growth by PDTC at non-toxic doses support a
potential use of this compound or other drugs having similar
stressing specific effects in clinical trials.
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